Xenon Pharmaceuticals (XENE) News Today $32.76 -0.04 (-0.12%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$32.76 0.00 (0.00%) As of 06/13/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by BrokeragesJune 15 at 1:51 AM | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from AnalystsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has been assigned an average rating of "Buy" from the twelve research firms that are presently covering the firm, Marketbeat reports. Twelve research analysts have rated the stock with a buy recommendation. The average 1 year target priceJune 15 at 1:50 AM | marketbeat.comBrokers Set Expectations for XENE FY2026 EarningsJune 12 at 3:24 AM | americanbankingnews.comTraders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 4,063 put options on the company. This represents an increase of approximately 2,362% compared to the average daily volume of 165 put options.June 12 at 2:09 AM | marketbeat.comCantor Fitzgerald Estimates XENE FY2026 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Xenon Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the biopharmaceuticalJune 10, 2025 | marketbeat.comXenon to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 17.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 191,852 shareJune 2, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DEBank of America Corp DE lessened its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 16.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 106,906 shares of the biopharmaceutical company's stock after sellinMay 31, 2025 | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2025 | globenewswire.comXenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading on Wednesday. Traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical volume of 165 put options.May 30, 2025 | marketbeat.comAmeriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Ameriprise Financial Inc. lifted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 39.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 92,350 shares of the biopharmaceutical coMay 28, 2025 | marketbeat.comWoodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Woodline Partners LP bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 39,938 shares of the biopharmaceutical company's stock, valued at approximately $1,566,000. WoodMay 27, 2025 | marketbeat.comTwo Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Two Sigma Investments LP increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 273,352 shares of the biopharmaceuticalMay 27, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLCMillennium Management LLC raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 65.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 346,040 shares of the biopharmaceutical company'sMay 26, 2025 | marketbeat.comNorthern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Northern Trust Corp raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 51.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,783 shares of the biopharmaceutical compMay 26, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LPTwo Sigma Advisers LP lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 298,700 shares of the biopharmaceutical company's stock after purchasMay 25, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.comStockNews.com downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday.May 23, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by BrokeragesShares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have received a consensus rating of "Buy" from the twelve ratings firms that are covering the firm, Marketbeat.com reports. Twelve research analysts have rated the stock with a buy recommendation. The average twelve-month price oMay 23, 2025 | marketbeat.comFair Value analysis proves accurate as XENE drops 37% from February 2024 peakMay 21, 2025 | investing.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LPVestal Point Capital LP lessened its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 810,000 shares of theMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)D. E. Shaw & Co. Inc. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 57.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,973 shares of the biopharmaceutical company's stoMay 21, 2025 | marketbeat.comEnsign Peak Advisors Inc Sells 136,970 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Ensign Peak Advisors Inc cut its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 84.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,094 shares of the biopharmaceutical company's stock after selliMay 19, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for XENE EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Analysts at Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research note issued on Tuesday, May 13th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceuticalMay 18, 2025 | marketbeat.comSphera Funds Management LTD. Acquires Shares of 52,097 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Sphera Funds Management LTD. acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 52,097 shares of the biopharmaceutical company'sMay 18, 2025 | marketbeat.comPolar Capital Holdings Plc Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Polar Capital Holdings Plc increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 10.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,697,657 shares oMay 17, 2025 | marketbeat.comHC Wainwright Issues Positive Outlook for XENE EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for Xenon Pharmaceuticals in a research note issued to investors on Tuesday, May 13th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company wilMay 17, 2025 | marketbeat.comTraders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the average volume of 165 put options.May 17, 2025 | marketbeat.comMPM Bioimpact LLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)MPM Bioimpact LLC raised its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 18.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 197,212 shares of the biopharmaceutical company's stock afterMay 16, 2025 | marketbeat.comWhy Xenon Pharmaceuticals Inc. (XENE) Declined on TuesdayMay 15, 2025 | insidermonkey.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst DowngradeXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down Following Analyst DowngradeMay 15, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday.May 15, 2025 | marketbeat.comXenon MRI Featured Prominently at ATS 2025 Across Broad Clinical SpectrumMay 15, 2025 | globenewswire.comXenon Pharmaceuticals' (XENE) Buy Rating Reiterated at Chardan CapitalChardan Capital restated a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday.May 15, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Lowered to $55.00 at Needham & Company LLCNeedham & Company LLC cut their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday.May 15, 2025 | marketbeat.comOrbimed Advisors LLC Has $37.16 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Orbimed Advisors LLC raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 947,877 shares of the biopharmaceuticalMay 15, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comEvercore ISI Group Initiates Coverage of Xenon Pharmaceuticals (XENE) with Outperform RecommendationMay 15, 2025 | msn.comJanus Henderson Group PLC Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Janus Henderson Group PLC increased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,866,755 shares of the biopharmaceutMay 15, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Announces Earnings ResultsXenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.11.May 14, 2025 | marketbeat.comXenon to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 14, 2025 | globenewswire.comXenon Pharmaceuticals Inc.: Xenon Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deXenon Pharmaceuticals stock falls on delayed study resultsMay 13, 2025 | investing.comXenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ...May 13, 2025 | finance.yahoo.comXenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comXenon Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Granahan Investment Management LLCGranahan Investment Management LLC trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 182,333 shares of the biopharmaceutiMay 12, 2025 | marketbeat.comBalyasny Asset Management L.P. Buys 100,382 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Balyasny Asset Management L.P. raised its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 119.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 184,580 shares of the biMay 12, 2025 | marketbeat.comTudor Investment Corp ET AL Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Tudor Investment Corp ET AL decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 76.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,671 shares of the biopharmaceutical company's stock after selling 28,016 shares duringMay 12, 2025 | marketbeat.comDimensional Fund Advisors LP Reduces Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Dimensional Fund Advisors LP lessened its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 259,970 shares of the biopharmaceutical company's stock aftMay 12, 2025 | marketbeat.comDriehaus Capital Management LLC Has $177.21 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Driehaus Capital Management LLC cut its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,520,595 shares of the biopharmaMay 10, 2025 | marketbeat.com Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Media Mentions By Week XENE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼1.060.89▲Average Medical News Sentiment XENE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼105▲XENE Articles Average Week Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Blueprint Medicines News Roivant Sciences News Revolution Medicines News BridgeBio Pharma News Elanco Animal Health News Verona Pharma News Legend Biotech News TG Therapeutics News Grifols News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts